Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
about
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection modelAnalysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus.Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized studyInfluence of platelets and platelet microbicidal protein susceptibility on the fate of Staphylococcus aureus in an in vitro model of infective endocarditis.Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionIn vivo pharmacodynamic activity of the glycopeptide dalbavancinCorrelation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database reviewIn vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains.Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model.Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.Once-daily gentamicin administration for community-associated methicillin resistant Staphylococcus aureus in an in vitro pharmacodynamic model: preliminary reports for the advantages for optimizing pharmacodynamic index.
P2860
Q33593883-0D88BE0D-DC96-4BD2-A491-FBE1FEF207E2Q33977356-C1E46859-7400-4E9D-A907-400160C1E233Q33982863-8AF72A5E-5EC0-48BA-96CA-F2256C5FFC19Q34007865-802AC2DF-D5A6-4F7C-BB00-71C4D03DF7AAQ34937444-ECD84DA4-0DBB-4B36-9BEE-77D84277E0C2Q35759076-B6419E5E-3392-4946-B682-6191289CF5AEQ36290499-B0763B81-6F55-4A07-9300-19471455A54EQ39537168-269B1CA5-C2E1-4723-9382-D35EB6334397Q40345173-6C3C2ED1-E9D6-494E-A0B2-FE99B7FC0E80Q40601946-7F31704A-E6B9-415A-A7D4-E5B7D58EF135Q41877860-939932FB-C34B-4239-A25F-08B2A464027D
P2860
Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Pharmacodynamics of vancomycin ...... n an in vitro infection model.
@ast
Pharmacodynamics of vancomycin ...... n an in vitro infection model.
@en
type
label
Pharmacodynamics of vancomycin ...... n an in vitro infection model.
@ast
Pharmacodynamics of vancomycin ...... n an in vitro infection model.
@en
prefLabel
Pharmacodynamics of vancomycin ...... n an in vitro infection model.
@ast
Pharmacodynamics of vancomycin ...... n an in vitro infection model.
@en
P2093
P2860
P356
P1476
Pharmacodynamics of vancomycin ...... in an in vitro infection model
@en
P2093
P2860
P304
P356
10.1128/AAC.41.11.2497
P407
P577
1997-11-01T00:00:00Z